131 I/ 123 I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging

Bombardieri, Emilio; Aktolun, Cumali; Baüm, Richard; Bishof-Delaloye, Angelika; Buscombe, J. R.; Chatal, J F; Maffioli, Lorenzo; Moncayo, Roy; Mortelmans, Luc; Reske, Sven N.

doi:10.1007/s00259-003-1357-0

Cited by 32 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A dose of 150-266 MBq of 123 I-MIBG was injected intravenously. After 24 h, anterior and posterior whole-body scans were acquired using a dual-head camera with a low-energy general-purpose parallel-hole collimator, favoring higher sensitivity (18,19), and a low-dose CT unit (VG Hawkeye or Precedence 16-slice) with the patient supine. Static images were acquired over 15 min with a matrix size of 256 · 256.…”

Section: I-mibg Scintigraphymentioning

confidence: 99%

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Binderup¹,

Knigge²,

Loft³

et al. 2010

J Nucl Med

253

164

View full text Add to dashboard Cite

Functional techniques are playing a pivotal role in the imaging of cancer today. Our aim was to compare, on a head-to-head basis, 3 functional imaging techniques in patients with histologically verified neuroendocrine tumors: somatostatin receptor scintigraphy (SRS) with 111 In-diethylenetriaminepentaacetic acidoctreotide, scintigraphy with 123 I-metaiodobenzylguanidine (MIBG), and 18 F-FDG PET. Methods: Ninety-six prospectively enrolled patients with neuroendocrine tumors underwent SRS, 123 I-MIBG scintigraphy, and 18 F-FDG PET on average within 40 d. The functional images were fused with low-dose CT scans for anatomic localization, and the imaging results were compared with the proliferation index as determined by Ki67. Results: The overall sensitivity of SRS, 123 I-MIBG scintigraphy, and 18 F-FDG PET was 89%, 52%, and 58%, respectively. Of the 11 SRS-negative patients, 7 were 18 F-FDG PET-positive, of which 3 were also 123 I-MIBG scintigraphypositive, giving a combined overall sensitivity of 96%. SRS also exceeded 123 I-MIBG scintigraphy and 18 F-FDG PET based on the number of lesions detected (393, 185, and 225, respectively) and tumor subtypes. 123 I-MIBG scintigraphy was superior to 18 F-FDG PET for ileal neuroendocrine tumors, and 18 F-FDG PET was superior to 123 I-MIBG scintigraphy for pancreaticoduodenal neuroendocrine tumors. The sensitivity of 18 F-FDG PET (92%) exceeded that of both SRS (69%) and 123 I-MIBG scintigraphy (46%) for tumors with a proliferation index above 15%. Conclusion: The overall sensitivity of 123 I-MIBG scintigraphy and 18 F-FDG PET was low compared with SRS. However, for tumors with a high proliferation rate, 18 F-FDG PET had the highest sensitivity. The results indicate that, although SRS should still be the routine method, 18 F-FDG PET provides complementary diagnostic information and is of value for neuroendocrine tumor patients with negative SRS findings or a high proliferation index.

show abstract

Section: I-mibg Scintigraphymentioning

confidence: 99%

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Binderup¹,

Knigge²,

Loft³

et al. 2010

J Nucl Med

253

164

View full text Add to dashboard Cite

show abstract

“…One scan was obtained using an Infinia (GE Healthcare) dual-head g camera. Both Siemens scanners were equipped with a medium-energy low-penetration parallel-hole collimator and calibrated in accordance with the European Association of Nuclear Medicine guidelines for 123 I-MIBG scintigraphy (28). The acquisition matrix size was 128 · 128.…”

Section: Imaging Proceduresmentioning

confidence: 99%

Semiquantitative ¹²³I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters

et al. 2015

View full text Add to dashboard Cite

123 I-metaiodobenzylguanidine ( 123 I-MIBG) scintigraphy plays an important role in the diagnostic evaluation of patients with pheochromocytoma and paraganglioma (PPGL). 123 I-MIBG targets cell membrane and vesicular catecholamine transporters of chromaffin cells and facilitates localization of the primary tumor and metastatic lesions. Its specificity for the diagnosis of adrenomedullary chromaffin cell tumors can be jeopardized by physiologic uptake by the normal adrenal medulla. The aim of this study was to distinguish between PPGLs and normal adrenal glands by evaluating semiquantitative 123 I-MIBG uptake and to examine genotype-specific differences in correlation with expression of catecholamine transporter systems. Methods: Sixty-two PPGLs collected from 57 patients with hereditary mutations in SDHA (n 5 1), SDHB (n 5 2), and SDHD (n 5 4) (SDH is succinate dehydrogenase); von Hippel-Lindau (VHL; n 5 2); RET (n 5 12); neurofibromin 1 (NF1; n 5 2); and MYC-associated factor X (MAX; n 5 1), and with sporadic PPGLs (n 5 33) were investigated. Preoperative planar and SPECT images were semiquantitatively analyzed using uptake measurements. Tumor-to-liver and normal adrenal-to-liver ratios were calculated and correlated with clinical characteristics including genotype, tumor size, and plasma metanephrines concentrations. The expression of norepinephrine transporter (NET) and vesicular monoamine transporter (VMAT-1) was evaluated immunohistochemically in paraffin-embedded tumor tissues. Results: Mean tumor-to-liver ratios of PPGL lesions were significantly higher than normal adrenal-to-liver ratios (P , 0.001). Cutoff values to distinguish between physiologic and pathologic adrenal uptake were established at 0.7 (100% sensitivity, 10.3% specificity) and 4.3 (100% specificity, 66.1% sensitivity). No statistically significant differences in 123 I-MIBG uptake were found across PPGLs of different genotypes. Mean NET expression in hereditary cluster 2 (RET, NF1, MAX) and apparently sporadic tumors was significantly higher than for hereditary cluster 1 (SDHx, VHL) PPGLs (P 5 0.011 and 0.006, respectively). Mean VMAT-1 expression in hereditary cluster 1 PPGLs was significantly higher than for cluster 2 tumors (P 5 0.010). 123 I-MIBG uptake significantly correlated with maximum tumor diameter (P 5 0.002). 123 I-MIBG uptake, however, did not correlate with either NET or VMAT-1 expression. Conclusion: Liver-normalized semiquantitative 123 I-MIBG uptake may be helpful to distinguish between pheochromocytoma and physiologic adrenal uptake. Genotype-specific differences in the expression of NET and VMAT-1 do not translate into differences in 123 I-MIBG uptake.

show abstract

“…In clinical practice, imaging of the cardiac sympathetic nerves is commonly performed 4 h after 123 I-MIBG injection, whereas a time interval of 24 h after injection is used to visualize tumors from neuroendocrine origin (11,12). Therefore, we compared 123 I-MIBG SPECT/CT images obtained 4 and 24 h after 123 I-MIBG administration and determined which time interval resulted in an optimal correlation with 18 F-FDG PET/CT-assessed BAT activity.…”

mentioning

confidence: 99%

Combining ¹²³I-Metaiodobenzylguanidine SPECT/CT and ¹⁸F-FDG PET/CT for the Assessment of Brown Adipose Tissue Activity in Humans During Cold Exposure

et al. 2013

View full text Add to dashboard Cite

131 I/ 123 I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging

Cited by 32 publications

References 15 publications

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Semiquantitative ¹²³I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters

Combining ¹²³I-Metaiodobenzylguanidine SPECT/CT and ¹⁸F-FDG PET/CT for the Assessment of Brown Adipose Tissue Activity in Humans During Cold Exposure

Contact Info

Product

Resources

About

131 I/ 123 I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging

Cited by 32 publications

References 15 publications

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters

Combining 123I-Metaiodobenzylguanidine SPECT/CT and 18F-FDG PET/CT for the Assessment of Brown Adipose Tissue Activity in Humans During Cold Exposure

Contact Info

Product

Resources

About

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Semiquantitative ¹²³I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters

Combining ¹²³I-Metaiodobenzylguanidine SPECT/CT and ¹⁸F-FDG PET/CT for the Assessment of Brown Adipose Tissue Activity in Humans During Cold Exposure